You are here:

infliximab (Remicade)

Advice

following a resubmission:

infliximab (Remicade®) is not recommended for use within NHS Scotland.

Indication under review: Treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.

In two randomised controlled studies, infliximab 5mg/kg intravenous infusion on weeks 0, 2 and 6 was significantly superior to placebo for the endpoint of clinical response at week eight.

The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.

Drug Details

Drug Name: infliximab (Remicade)
SMC Drug ID: 374/07
Manufacturer: MSD
Indication: treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.
BNF Category:
Sub Category: 1.5 Chronic bowel disorders
Submission Type: Resubmission
Status: Superseded
Date Advice Published: 12 May 2014

Archived Advice

Non submission 7 May 2007

Back